Aggressive oligodendroglioma: a chemosensitive tumor.
Cairncross
J G
JG
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
D000477:Alkylating Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000601:surgery; D011344:Procarbazine / Q000008:administration & dosage; D016879:Salvage Therapy; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D000477:Alkylating Agents; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine